An informational webinar (Web-based seminar) about the trial will be held Wednesday, Feb. 9, 2011, at 2 p.m. EST, for anyone interested in learning more. It will be presented by neurologist Merit Cudkowicz, who is the principal investigator on the trial and director of the MDA/ALS Center at Massachusetts General Hospital in Boston.
Cudkowicz (pronounced “Suh-KO-vitch”) will describe the procedures used in the study, explain the scientific rationale behind the trial, and will be available to answer questions from webinar participants.
Ceftriaxone is an antibiotic that may confer neuroprotective benefits to the motor neurons (nerve cells) that die off in ALS. For more information, see Clinical Trial of Ceftriaxone in Subjects With ALS.
Those interested in viewing the webinar may click here to register. Early registration is recommended, as space is limited. After signing up, webinar participants will receive a confirmation e-mail with call-in instructions for the U.S. and Canada.
For more information, contact Sarah Titus, assistant project manager, at (617) 726-1398, or e-mail email@example.com